Skip to content
  • Monday, 29 June 2026
  • 9:11 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Pharmaceutical R&D

Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition

Teuku Ryan Jun 29, 2026 0

Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…

Read More
Pharmaceutical R&D

Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion to Bolster Immunology and Rare Disease Portfolio

Teuku Ryan Apr 1, 2026 0

Biogen, a global biotechnology company renowned for its pioneering work in neuroscience, has announced a significant strategic acquisition of Apellis…

Read More
NASA Upgrades Cold Atom Lab to Advance Quantum Research on International Space StationYour brain can keep improving into your 90s, study findsThe Architecture of Intelligence Notre Dame Researchers Reveal How Whole Brain Coordination Defines the Unified MindBreakthrough in Solar Energy Conversion Efficiency Surpasses Theoretical Limits via Singlet Fission and Molybdenum Spin-Flip Emitters
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveHigh-Dimensional Topological Structures Discovered in Entangled Photons Offer New Framework for Quantum Information StabilityWater-in-Diesel Emulsion Technology Offers Significant Emissions Reduction Potential Without Engine Modification
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sBiogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion AcquisitionThe Evolving Landscape of Retrieval-Augmented Generation: Addressing Production Failures and Exploring Advanced AlternativesMicrobial Allies: Naturally Occurring Soil Bacteria Offer Hope Against the Growing Threat of Saline Agriculture
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jun 29, 2026
Pharmaceutical R&D
Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Teuku Ryan Jun 29, 2026
Data Science & Bioinformatics
The Evolving Landscape of Retrieval-Augmented Generation: Addressing Production Failures and Exploring Advanced Alternatives
Evan Lee Salim Jun 29, 2026
Molecular & Cell Biology
Microbial Allies: Naturally Occurring Soil Bacteria Offer Hope Against the Growing Threat of Saline Agriculture
Angie Faith Jun 29, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ